Retatrutide posted the biggest weight-loss numbers yet — and you still can't legally buy it anywhere

Retatrutide is the compound the obesity field has been watching, and over the past seven months it finally delivered Phase 3 data. The short version is easy to state and easy to misunderstand: the weight-loss numbers are the largest ever reported for a GLP-1-class drug — and there is not a single country on earth where you can lawfully buy it. Both of those things are true at once, and the gap between them is the whole story.

What it actually is

Retatrutide (Eli Lilly’s LY3437943) is a once-weekly injectable triple agonist: it activates the GLP-1, GIP, and glucagon receptors. Semaglutide (Ozempic, Wegovy) hits one of those; tirzepatide (Mounjaro, Zepbound) hits two. Adding glucagon-receptor activity is the theoretical basis for pushing energy expenditure higher on top of appetite suppression — and so far the Phase 3 data are consistent with that idea.

The Phase 3 signal

• TRIUMPH-4 (68 weeks; adults with obesity and knee osteoarthritis, no diabetes): average weight loss of 28.7% at the 12 mg dose versus 2.1% on placebo, alongside a large reduction in knee-pain scores.
• TRIUMPH-1 (2,339 participants, 80 weeks): 25.0% at 12 mg, 23.7% at 9 mg, and 17.6% at 4 mg, versus 3.9% on placebo. A subgroup with BMI ≥ 35 who continued to 104 weeks reached roughly 30%.

For context, tirzepatide and semaglutide landed near ~20% in their own pivotal trials. Retatrutide is, as of now, the highest weight-loss figure the class has produced.

The honest caveats

This is not a finished story, and the numbers above are not a license to go looking for a vial. Discontinuation from side effects ran 12–18% at the higher doses (versus about 4% on placebo), driven by nausea, diarrhea, and constipation — the familiar incretin GI profile, amplified. All of the data come from a single sponsor, and the long-term cardiovascular-outcome and safety readouts are still pending across the remaining TRIUMPH trials. Impressive top-line efficacy and a complete safety picture are different milestones, and only the first has been reached.

Who is actually making it

There are two answers, and they are not the same.

The legitimate manufacturer is Eli Lilly, which developed retatrutide (drug code LY3437943), owns the clinical program, and states plainly that the molecule “is legally available only to participants in Lilly’s clinical trials.” Nobody else is lawfully producing a finished retatrutide product for patients.

The gray-market supply is a different world. The vials sold online as “retatrutide,” “reta,” or “Triple G” are lyophilized powder synthesized by Chinese peptide and API labs — solid-phase peptide synthesis is inexpensive and widely available there — and resold by “research chemical” vendors, typically for $180–$280 per 10 mg vial. These are not FDA-registered facilities, and the products are deliberately labeled “for research use only” and “not for human consumption” — a legal fig-leaf that lets the seller sit on the research-chemical side of the line while the actual customer base draws it into a syringe. Independent testing tells you why that matters: the FDA has reported that up to ~40% of online and “compounded” peptides contained incorrect dosages or undeclared ingredients, and independent labs have found bacterial endotoxins, heavy metals, truncated peptide sequences, and in some cases an entirely different molecule than the label claims. Vendor “certificates of analysis” are frequently self-generated or from unaccredited labs.

Where you can legally get it

Nowhere, if “get it” means buy it. As of mid-2026 retatrutide is investigational in every country — not approved by the FDA, the EMA, the UK’s MHRA, Australia’s TGA, Health Canada, China’s NMPA, or Japan’s PMDA. No marketing authorization anywhere means no lawful prescription and no lawful retail sale anywhere.

• Phase 3 TRIUMPH trial site — enrollment only, not for sale
• Not approved — no lawful way to buy or be prescribed it

Retatrutide is not approved for marketing in any country. The amber countries are the 13 nations running Lilly's Phase 3 TRIUMPH program (Giblin et al., Diabetes, Obesity & Metabolism, 2026); being an amber country means you may be able to enroll in a trial there — it does not mean the drug can be bought or prescribed. Everywhere else, and in the amber countries outside a trial, there is no lawful consumer route. Lilly also runs a narrow pre-approval expanded-access (compassionate-use) program that a physician must initiate.

What the amber countries on that map represent is worth stating carefully, because it is the single most misread fact about retatrutide. Those 13 nations are where Lilly runs its Phase 3 TRIUMPH program — so a resident there may be able to enroll in a trial. Enrolling is not buying: you might receive placebo, the drug is dispensed and supervised by the trial, and enrollment closes as the trials complete. Lilly also runs a narrow pre-approval expanded-access (compassionate-use) program that a physician has to initiate case by case — again lawful, again not a purchase channel. Every other route calling itself “access” is not legal access at all.

This is also why the medical-tourism playbook that works for other drugs does nothing here. People fly to Mexico for tirzepatide because it is an approved drug there, just cheaper. Retatrutide is approved in exactly zero of those destinations, so a plane ticket relocates you to the same trial-or-gray-market choice you had at home.

How people are actually getting it

Setting the lawful trial and expanded-access routes aside, real-world access falls into three buckets, in descending order of legitimacy:

1. Clinical-trial enrollment — the only fully lawful, supervised route. Free drug, real medical oversight, and a real chance of placebo.
2. Gray-market “research chemical” vials — the Chinese-sourced powder described above. This is how the overwhelming majority of non-trial users obtain it, and it is unapproved, unverified for identity, dose, purity, or sterility, and taken with no clinical supervision.
3. “Compounded retatrutide” sold by telehealth or wellness sellers — marketed to sound like the compounded-semaglutide and compounded-tirzepatide arrangements people got used to during the shortage era. It is not the same thing, and it is not legal. Because there is no approved retatrutide product, no USP monograph, and no listing on the FDA’s 503A or 503B bulk drug-substance lists, retatrutide cannot lawfully be compounded at all. The FDA has said so directly and has sent warning letters to compounders and telehealth firms selling it — including a March 2026 warning letter naming a vendor offering “Retatrutide” as an unapproved new drug, and a broader crackdown on misleading compounded-GLP-1 advertising.

The through-line across buckets 2 and 3 is that the honest question isn’t only “does retatrutide work” — the Phase 3 data suggest it works well — it’s “does this vial contain what the label says, at the dose it says, without anything else in it,” and for gray-market product the answer is that nobody you can hold accountable has checked.

Bottom line

Genuinely promising drug, genuinely unfinished evidence, and genuinely not something to source from a gray-market vial. On analyst projections — not company commitments — a US filing could come around late 2026 or early 2027, with an earliest realistic approval window of roughly 2027–2028, and other regulators later still. Until then, retatrutide is a clean test of a habit worth building: separating the science (real, strong, still accumulating) from the supply chain (“available online” is not “approved,” “verified,” or “safe”). It fits the broader pattern of the peptide conversation flattening approved drugs, investigational drugs, and research chemicals into one word — the subject of the peptide craze, in context. For the full regulatory and trial detail, see the retatrutide reference page.